Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Orchard Therapeutics plc (ORTX)

0.57   -0.014 (-2.43%) 07-02 18:44
Open: 0.57 Pre. Close: 0.5842
High: 0.62 Low: 0.56
Volume: 1,417,680 Market Cap: 72(M)
Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.62 - 0.62 0.62 - 0.63
Low: 0.55 - 0.56 0.56 - 0.56
Close: 0.56 - 0.57 0.57 - 0.58

Technical analysis

as of: 2022-07-01 4:24:13 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 0.74     One year: 0.87
Support: Support1: 0.52    Support2: 0.44
Resistance: Resistance1: 0.63    Resistance2: 0.74
Pivot: 0.56
Moving Average: MA(5): 0.57     MA(20): 0.54
MA(100): 0.66     MA(250): 1.48
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 62.4     %D(3): 60.6
RSI: RSI(14): 53.9
52-week: High: 4  Low: 0.4
Average Vol(K): 3-Month: 790 (K)  10-Days: 1,478 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ORTX ] has closed below upper band by 46.8%. Bollinger Bands are 43% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Sat, 18 Jun 2022
Orchard Therapeutics (NASDAQ:ORTX) & Miromatrix Medical (NASDAQ:MIRO) Head-To-Head Comparison - Defense World

Thu, 26 May 2022
$3.86 Million in Sales Expected for Orchard Therapeutics plc (NASDAQ:ORTX) This Quarter - Defense World

Thu, 12 May 2022
Orchard Therapeutics PLC (ORTX) CEO Bobby Gaspar on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha

Tue, 10 May 2022
Orchard Therapeutics Announces Presentations at ASGCT 2022 Showcasing Potential of HSC Gene Therapy in Neurodegenerative Disorders and Beyond - Yahoo Finance

Tue, 29 Mar 2022
Pre-Market Earnings Report for March 30, 2022 : PAYX, BNTX, FIVE, AER, MSM, UNF, AXLA, TCRT, ORTX, CAAS, PTE - Nasdaq

Mon, 21 Mar 2022
What Kind Of Shareholders Hold The Majority In Orchard Therapeutics plc's (NASDAQ:ORTX) Shares? - Simply Wall St

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 126 (M)
% Held by Insiders 7.152e+007 (%)
% Held by Institutions 0.4 (%)
Shares Short 1,540 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.3811e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -8
Return on Assets (ttm) 384
Return on Equity (ttm) -29.2
Qtrly Rev. Growth 1.68e+006
Gross Profit (p.s.) 0
Sales Per Share -64.74
EBITDA (p.s.) -7.43739e+007
Qtrly Earnings Growth -1.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -125 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 0.33

Stock Dividends

Dividend 0
Forward Dividend 777940
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.